Shared on 01 Nov 25
Fair value Increased 1.58%Analysts have raised their price target for Exact Sciences to $70 from $60, citing continued strength in its core Cologuard franchise as well as expanding opportunities in cancer screening and detection. Analyst Commentary Recent analyst activity for Exact Sciences reflects a dynamic mix of optimism and caution, as the company continues to execute on its core strengths while navigating evolving market expectations.
Shared on 18 Oct 25
Fair value Increased 5.78%Analysts have raised their price target for Exact Sciences to approximately $70 from $65, citing strong momentum from new revenue opportunities and increased confidence in long-term growth drivers. Analyst Commentary Recent analyst actions on Exact Sciences reflect notable shifts in sentiment, both positive and cautious, following the company’s latest performance and strategic moves.
Shared on 03 Oct 25
Fair value Increased 2.13%Analysts have modestly raised their price target for Exact Sciences, increasing it from $64.01 to $65.38. They cite incremental near-term revenue growth drivers, ongoing margin expansion, and improved cash flow prospects as key reasons for the upward adjustment.
Shared on 12 Sep 25
Fair value Increased 1.38%Analysts have modestly raised Exact Sciences’ price target to $64.01, citing renewed optimism from the Freenome deal and Shield V2 data as potential growth catalysts despite near-term skepticism around CRC blood-test data, resulting in only a slight upward revision to fair value. Analyst Commentary Bullish analysts cite the Freenome deal and Shield V2 data as catalysts for renewed Street focus on execution, with multiple near-term revenue growth drivers, continued EBITDA margin expansion, improving cash flow, and possible estimate upside.
Shared on 08 Aug 25
Fair value Decreased 2.25%Despite a slight rise in Exact Sciences’ future P/E ratio and a modest decline in its net profit margin, the consensus analyst price target remains unchanged at $64.60. What's in the News Exact Sciences raised full-year 2025 revenue guidance to $3.13–$3.17 billion, up from previous estimates of $3.07–$3.12 billion, reflecting strong business momentum (Key Developments, 2025-08-06).